Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Interoperable Electronic Health Records and Health Information Exchanges: Systematic Review.

Dobrow MJ, Bytautas JP, Tharmalingam S, Hagens S.

JMIR Med Inform. 2019 Jun 6;7(2):e12607. doi: 10.2196/12607. Review.

2.

Complete Genome Sequences of Escherichia coli Phages vB_EcoM-EP75 and vB_EcoP-EP335.

van Mierlo J, Hagens S, Witte S, Klamert S, van de Straat L, Fieseler L.

Microbiol Resour Announc. 2019 Apr 18;8(16). pii: e00078-19. doi: 10.1128/MRA.00078-19.

3.

Organ involvement occurs in all forms of hereditary haemolytic anaemia.

van Straaten S, Verhoeven J, Hagens S, Schutgens R, van Solinge W, van Wijk R, van Beers EJ.

Br J Haematol. 2019 May;185(3):602-605. doi: 10.1111/bjh.15575. Epub 2018 Sep 5. No abstract available.

PMID:
30183081
4.

Passive acoustic surveys for predicting species' distributions: Optimising detection probability.

Hagens SV, Rendall AR, Whisson DA.

PLoS One. 2018 Jul 18;13(7):e0199396. doi: 10.1371/journal.pone.0199396. eCollection 2018.

5.

Connecting Families to Their Health Record and Care Team: The Use, Utility, and Impact of a Client/Family Health Portal at a Children's Rehabilitation Hospital.

King G, Maxwell J, Karmali A, Hagens S, Pinto M, Williams L, Adamson K.

J Med Internet Res. 2017 Apr 6;19(4):e97. doi: 10.2196/jmir.6811.

6.

The Need for Electronic Health Records in Long-Term Care.

Tharmalingam S, Hagens S, English S.

Stud Health Technol Inform. 2017;234:315-320.

PMID:
28186061
7.

Novel Approaches to Digital Health Evaluation Capacity Building.

Hagens S, Tharmalingam S.

Stud Health Technol Inform. 2017;234:156-160.

PMID:
28186033
8.

Use and Maturity of Electronic Patient Portals.

Gheorghiu B, Hagens S.

Stud Health Technol Inform. 2017;234:136-141.

PMID:
28186030
9.

The value of connected health information: perceptions of electronic health record users in Canada.

Tharmalingam S, Hagens S, Zelmer J.

BMC Med Inform Decis Mak. 2016 Jul 16;16:93. doi: 10.1186/s12911-016-0330-3.

10.

Measuring interoperable EHR adoption and maturity: a Canadian example.

Gheorghiu B, Hagens S.

BMC Med Inform Decis Mak. 2016 Jan 25;16:8. doi: 10.1186/s12911-016-0247-x.

11.

The Effects of Web-Based Patient Access to Laboratory Results in British Columbia: A Patient Survey on Comprehension and Anxiety.

Mák G, Smith Fowler H, Leaver C, Hagens S, Zelmer J.

J Med Internet Res. 2015 Aug 4;17(8):e191. doi: 10.2196/jmir.4350.

12.

Valuing national effects of digital health investments: an applied method.

Hagens S, Zelmer J, Frazer C, Gheorghiu B, Leaver C.

Stud Health Technol Inform. 2015;208:165-9.

PMID:
25676967
13.

Impact of information technology on information gaps in canadian ambulatory care encounters.

Korosec L, Balenko K, Hagens S.

JMIR Med Inform. 2015 Jan 8;3(1):e1. doi: 10.2196/medinform.4066.

14.

Understanding the gap between desire for and use of consumer health solutions.

Zelmer J, Hagens S.

Healthc Pap. 2014;13(4):9-21.

PMID:
25148119
15.

Phages of Listeria offer novel tools for diagnostics and biocontrol.

Hagens S, Loessner MJ.

Front Microbiol. 2014 Apr 10;5:159. doi: 10.3389/fmicb.2014.00159. eCollection 2014. Review.

16.
17.

Genome Sequence of Salmonella bongori Strain N268-08.

Marti R, Hagens S, Loessner MJ, Klumpp J.

Genome Announc. 2013 Dec 12;1(6). pii: e01018-13. doi: 10.1128/genomeA.01018-13. No abstract available.

18.

Genome Sequence of Salmonella bongori Strain N268-08 [corrected].

Marti R, Hagens S, Loessner MJ, Klumpp J.

Genome Announc. 2013 Aug 22;1(4). pii: e00580-13. doi: 10.1128/genomeA.00580-13. Erratum in: Genome Announc. 2013 Dec 12;1(6):null.

19.

Knowledge translation in eHealth: building a virtual community.

Bassi J, Lau F, Hagens S, Leaver C, Price M.

Stud Health Technol Inform. 2013;183:257-62.

PMID:
23388294
20.

Long tail fibres of the novel broad-host-range T-even bacteriophage S16 specifically recognize Salmonella OmpC.

Marti R, Zurfluh K, Hagens S, Pianezzi J, Klumpp J, Loessner MJ.

Mol Microbiol. 2013 Feb;87(4):818-34. doi: 10.1111/mmi.12134. Epub 2013 Jan 15.

21.

Drug information systems: evolution of benefits with system maturity.

Leung V, Hagens S, Zelmer J.

Healthc Q. 2013;16(2):43-8.

PMID:
24863449
22.
23.

Bacteriophage applications: where are we now?

Monk AB, Rees CD, Barrow P, Hagens S, Harper DR.

Lett Appl Microbiol. 2010 Oct;51(4):363-9. doi: 10.1111/j.1472-765X.2010.02916.x. Epub 2010 Aug 26.

24.

Potential misuse of an antimicrobial resulting from a miscalculation in an efficacy study.

Hagens S.

J Food Sci. 2010 Jan-Feb;75(1):ix; author reply ix. doi: 10.1111/j.1750-3841.2009.01498.x. No abstract available.

PMID:
20492212
25.

Reduction of Listeria monocytogenes on the surface of fresh channel catfish fillets by bacteriophage Listex P100.

Soni KA, Nannapaneni R, Hagens S.

Foodborne Pathog Dis. 2010 Apr;7(4):427-34. doi: 10.1089/fpd.2009.0432.

PMID:
19958102
26.

Evolution of a national approach to evaluating the benefits of the electronic health record.

Hagens S, Krose A.

Stud Health Technol Inform. 2009;143:389-94.

PMID:
19380966
27.

Findings from evaluations of the benefits of diagnostic imaging systems.

Hagens S, Kraetschmer N, Savege C.

Stud Health Technol Inform. 2009;143:136-41.

PMID:
19380927
28.

Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations.

Hagens S, Loessner MJ.

Curr Pharm Biotechnol. 2010 Jan;11(1):58-68. Review.

PMID:
20214608
29.

PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response.

Kim KP, Cha JD, Jang EH, Klumpp J, Hagens S, Hardt WD, Lee KY, Loessner MJ.

Microb Biotechnol. 2008 May;1(3):247-57. doi: 10.1111/j.1751-7915.2008.00028.x.

30.

Application of bacteriophages for detection and control of foodborne pathogens.

Hagens S, Loessner MJ.

Appl Microbiol Biotechnol. 2007 Sep;76(3):513-9. Epub 2007 Jun 7. Review.

PMID:
17554535
31.

A proposed benefits evaluation framework for health information systems in Canada.

Lau F, Hagens S, Muttitt S.

Healthc Q. 2007;10(1):112-6, 118.

PMID:
17326376
32.

A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions.

Noels H, van Loo G, Hagens S, Broeckx V, Beyaert R, Marynen P, Baens M.

J Biol Chem. 2007 Apr 6;282(14):10180-9. Epub 2007 Feb 7.

33.

The dark side of EGFP: defective polyubiquitination.

Baens M, Noels H, Broeckx V, Hagens S, Fevery S, Billiau AD, Vankelecom H, Marynen P.

PLoS One. 2006 Dec 20;1:e54.

34.

Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage.

Hagens S, Habel A, Bläsi U.

Microb Drug Resist. 2006 Fall;12(3):164-8.

PMID:
17002542
35.

Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination.

Baens M, Fevery S, Sagaert X, Noels H, Hagens S, Broeckx V, Billiau AD, De Wolf-Peeters C, Marynen P.

Cancer Res. 2006 May 15;66(10):5270-7.

36.

Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage.

Hagens S, Habel A, von Ahsen U, von Gabain A, Bläsi U.

Antimicrob Agents Chemother. 2004 Oct;48(10):3817-22.

37.

Reduced virulence of a hfq mutant of Pseudomonas aeruginosa O1.

Sonnleitner E, Hagens S, Rosenau F, Wilhelm S, Habel A, Jäger KE, Bläsi U.

Microb Pathog. 2003 Nov;35(5):217-28.

PMID:
14521880
38.

Genetically modified filamentous phage as bactericidal agents: a pilot study.

Hagens S, Bläsi U.

Lett Appl Microbiol. 2003;37(4):318-23.

39.
40.

Transfusion-acquired hepatitis A in a premature infant with secondary nosocomial spread in an intensive care nursery.

Azimi PH, Roberto RR, Guralnik J, Livermore T, Hoag S, Hagens S, Lugo N.

Am J Dis Child. 1986 Jan;140(1):23-7.

PMID:
3942103
41.

Anomalous antibody responses in viral infection: specific stimulation or polyclonal activation?

Cremer NE, Devlin VL, Riggs JL, Hagens SJ.

J Clin Microbiol. 1984 Sep;20(3):468-72.

42.

Improved serological diagnosis of rubella.

Cremer NE, Hagens SJ, Fukuchi R.

J Clin Microbiol. 1983 Sep;18(3):743-4.

43.

Cell-mediated cytotoxicity toward measles virus-infected target cells in randomly bred Syrian hamsters.

Cremer NE, O'Keefe B, Hagens SJ, Diggs J.

Infect Immun. 1982 Nov;38(2):580-7.

46.
47.

Complications and immunological studies of measles virus infection in antithymocyte-treated hamsters.

Cremer NE, Hagens SJ, Taylor DO, Lennette EH.

Infect Immun. 1977 Apr;16(1):155-62.

48.

IgM production in rats infected with Moloney leukemia virus.

Cremer NE, Taylor DO, Lennette EH, Hagens SJ.

J Natl Cancer Inst. 1973 Sep;51(3):908-15. No abstract available.

PMID:
4795514
49.

Antibody formation, latency and leukemia: infection with Moloney virus.

Cremer NE, Taylor DO, Hagens SJ.

J Immunol. 1966 Mar;96(3):495-508. No abstract available.

PMID:
5932581
50.

Difference in mechanism of viral neutralization under in vitro and in vivo conditions.

Cremer NE, Lennette EH, Hagens SJ, Fujimoto FY.

J Immunol. 1966 Feb;96(2):284-8. No abstract available.

PMID:
4160485

Supplemental Content

Loading ...
Support Center